Search results
We are passionate about patients and science. Join Us. We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
Jun 4, 2024 · Investors & News. Ascendis Pharma is applying our innovative TransCon™ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.
We have a diverse pipeline designed to make a meaningful difference for patients. Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon ® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development.
May 13, 2024 · We are passionate about patients and science. Join Us. We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs.
Dec 31, 2021 · Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update. - Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter. - Demand for SKYTROFA® (lonapegsomatropin-tcgd), the ...
Feb 16, 2023 · For the full year 2022, Ascendis Pharma reported a net loss of €583.2 million, or €10.40 per share (basic and diluted) compared to a net loss of €383.6 million, or €7.00 per share (basic and diluted) for the same period in 2021.
Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’...
Building on our success in endocrinology rare diseases, we aim to advance cancer treatments and improve patient outcomes. Over the last few decades, groundbreaking oncology research has accelerated our understanding of cancer biology and the mechanisms involved in these devastating diseases.
At the core of Ascendis Pharma is a powerful, flexible technology platform that uses advanced knowledge of chemistry to overcome challenges of developing new therapeutics. When applied using known biology, this technology platform helps us address unmet patient needs in unprecedented ways.
